Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 3
2015 2
2016 1
2017 2
2018 2
2019 5
2020 9
2021 14
2022 6
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J. Sánchez R, et al. Among authors: carreno tarragona g. Sci Rep. 2024 Mar 28;14(1):7400. doi: 10.1038/s41598-024-57570-5. Sci Rep. 2024. PMID: 38548834 Free PMC article. No abstract available.
DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.
Segura-Díaz A, Stuckey R, Florido Y, Sobas M, Álvarez-Larrán A, Ferrer-Marín F, Pérez-Encinas M, Carreño-Tarragona G, Fox ML, Tazón Vega B, Cuevas B, López Rodríguez JF, Farías-Sánchez N, González-Martín JM, Gómez-Casares MT, Bilbao-Sieyro C; Spanish MPN Group (GEMFIN). Segura-Díaz A, et al. Among authors: carreno tarragona g. Thromb Haemost. 2024 Jan 30. doi: 10.1055/a-2239-9265. Online ahead of print. Thromb Haemost. 2024. PMID: 38190984
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martínez-Banaclocha H, Hernández-Rivas JM, Marco-Ayala J, Martínez-Alarcón L, Linares-Latorre L, García-Ávila S, Amat-Martínez P, González T, Arnan M, Pomares-Marín H, Carreño-Tarragona G, Chen-Liang TH, Herranz MT, García-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrín P, Ferrer-Marín F. Hurtado-Navarro L, et al. Among authors: carreno tarragona g. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. Cell Rep Med. 2023. PMID: 38118408 Free PMC article.
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
Alvarez-Larrán A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Marín F, Carbonell S, Pérez-Encinas M, Gómez-Casares MT, Pérez-López R, Magro E, Moretó A, Pastor-Galán I, Angona A, Mata-Vázquez MI, Guerrero-Fernández L, Guerra JM, Carreño-Tarragona G, Fox L, Murillo I, García-Gutiérrez V, Mora E, Stuckey R, Arellano-Rodrigo E, Hernández-Boluda JC, Pereira A. Alvarez-Larrán A, et al. Among authors: carreno tarragona g. Hemasphere. 2023 Jul 18;7(8):e936. doi: 10.1097/HS9.0000000000000936. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37476303 Free PMC article.
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Morales ML, García-Vicente R, Rodríguez-García A, Reyes-Palomares A, Vincelle-Nieto Á, Álvarez N, Ortiz-Ruiz A, Garrido-García V, Giménez A, Carreño-Tarragona G, Sánchez R, Ayala R, Martínez-López J, Linares M. Morales ML, et al. Among authors: carreno tarragona g. Leukemia. 2023 Aug;37(8):1649-1659. doi: 10.1038/s41375-023-01963-4. Epub 2023 Jul 8. Leukemia. 2023. PMID: 37422594 Free PMC article.
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
Ayala R, Fernández RA, García-Gutiérrez V, Alvarez-Larrán A, Osorio S, Sánchez-Pina JM, Carreño-Tarragona G, Álvarez N, Gómez-Casares MT, Duran A, Gorrochategi J, Hernández-Boluda JC, Martínez-López J. Ayala R, et al. Among authors: carreno tarragona g. EJHaem. 2023 Apr 16;4(2):401-409. doi: 10.1002/jha2.685. eCollection 2023 May. EJHaem. 2023. PMID: 37206258 Free PMC article.
Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach.
Ríos-Tamayo R, Sánchez MJ, Gómez-Rojas S, Rodríguez-Barranco M, Segura GP, Redondo-Sánchez D, Carreño-Tarragona G, Nicolás AR, Ruiz-Cabello F, Jiménez P, Alonso R, Lahuerta JJ, Martínez-López J, Duarte RF. Ríos-Tamayo R, et al. Among authors: carreno tarragona g. Diagnostics (Basel). 2023 Mar 11;13(6):1071. doi: 10.3390/diagnostics13061071. Diagnostics (Basel). 2023. PMID: 36980379 Free PMC article.
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala R, Carreño-Tarragona G, Barragán E, Boluda B, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao C, Sánchez-García J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Pérez-Simón JA, Calbacho M, Alonso-Domínguez JM, Labrador J, Tormo M, Amigo ML, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz MJ, Gomez-Casares T, García-Sanz R, Sanz MA, Martínez-López J, Montesinos P. Ayala R, et al. Among authors: carreno tarragona g. Cancers (Basel). 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799. Cancers (Basel). 2022. PMID: 36497281 Free PMC article.
49 results